Compare Bristol-Myers Squibb Co (BMY) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Expeditors International of Wshngtn Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.56 (market cap $116.30B), while Expeditors International of Wshngtn Inc trades at $178.56 (market cap $23.31B). The key difference: Bristol-Myers Squibb Co is far larger — about 5× Expeditors International of Wshngtn Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | EXPD | |
|---|---|---|
Market Cap | $116.30B | $23.31B |
Sector | Health | Industrials |
52-Week High | $62.37 | $178.22 |
52-Week Low | $42.60 | $111.37 |
Enterprise Value | $152.24B | $22.56B |
Dividend Yield | 4.42% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EXPD trades at $175.50, up 2.02% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, revenue growth to $11.07B in 2025, and impressive ROE of 36.59%. Recent dividend payments and positive analyst coverage highlight financial stability, though valuation metrics appear elevated with P/E of 28.35.
Outlook remains positive with earnings momentum and e-commerce tailwinds, but risks include stretched valuation, mixed analyst sentiment (only 12% buy ratings), and economic sensitivity. The stock trades above consensus price target of $159, suggesting limited near-term upside potential despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
